Patent reform bill reported to House

Share this article:
The House Judiciary Committee voted before the summer congressional recess to approve and send to the House a bill observers said would overhaul the US patent system by weeding out bad patents and restraining excessive litigation over patents. The measure continues to be opposed by drug and biotech firms.

The bill reportedly would give parties more leeway to question patent validity and would limit damage awards in infringement cases.

“Past attempts at achieving comprehensive patent reform have met with stiff resistance,” said bill chief sponsor Rep. Howard Berman (D-CA).  

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.